Page last updated: 2024-10-30

leflunomide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

leflunomide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Avery, RK1
Bolwell, BJ1
Yen-Lieberman, B1
Lurain, N1
Waldman, WJ1
Longworth, DL1
Taege, AJ1
Mossad, SB1
Kohn, D1
Long, JR1
Curtis, J1
Kalaycio, M1
Pohlman, B1
Williams, JW1

Other Studies

1 other study available for leflunomide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
    Bone marrow transplantation, 2004, Volume: 34, Issue:12

    Topics: Bone Marrow Transplantation; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, Combi

2004